Sun Pharma gains after USFDA approval:Sun Pharmaceutical Industries advanced almost a percent to Rs 841.75 on BSE after the company said it received US drug regulator's approval for abbreviated new drug application for generic version of Glumetza tablets.The company will announce Q1 results on 12 August 2016.
Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 849, up by 8.6 points or 1.02% from its previous closing of Rs. 839.7 - See more at: http://ways2capital-equitytips.blogspot.in/2015/09/sun-pharmaceutical-may-divest.html#sthash.CPXETRiL.dpuf
Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets 100mg and 400mg Imatinib Mesylate tablets,
Here’s a round-up of the stories thus far: Reuters: FDA bans imports from Sun Pharma plant in India crackdown The U.S. Food and Drug Administration (FDA) has banned imports from Indian generic drugmaker Sun Pharmaceutical Industries Ltd’s plant at Karkhadi in the western state of Gujarat, in the latest quality blow for India’s drug sector. …
Sun Pharmaceutical Industries Ltd’s southward journey continues for yet another trading session. The scrip is currently trading 1.3% lower at Rs. 709.15 on BSE, which is a 16-month low level. - See more at: http://ways2capital-equitytips.blogspot.in/2015/11/sun-pharma-falls-13-pays-rs-500-cr.html#sthash.7RMIbaax.dpuf
Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 913, up by 1.7% from its previous closing of Rs. 898.2 on the BSE. - See more at: http://ways2capital-review.blogspot.in/2015/10/sun-pharma-up-17-ranbaxy.html#sthash.G7MF6dF5.dpuf
Investors bought more shares of Sun Pharmaceutical Industries on Monday on settlement of litigation with the US company. The stock rallied more than 4 percent to hit a record high of Rs 1,124.35. The drug maker has entered into a settlement pact with US-based The Medicines Company for settling the lawsuit filed against it by the later for generic Angiomax. - See more at: http://ways2capital.blogspot.in/2015/04/sun-pharma-up-4.html#sthash.M90lO67v.dpuf
Sun Pharmaceutical Industries Ltd. has recalled 68,000 bottles of the antidepressant Effexor in the U.S., in the second recall of the drug this year, the U.S. Food and Drug Administration said http://online.wsj.com/articles/sun-pharma-recalls-effexor-in-u-s-1416297616?mod=WSJ_LatestHeadlines
Shares of Sun Pharmaceutical Industries gained more than 1 percent Tuesday on completion of acquisition of Opiates business in Australia. - See more at: http://ways2capital-equitytips.blogspot.in/2015/09/sun-pharma-up-1-completes-acquisition.html#sthash.ns0cKyxJ.dpuf
Pharma major Dr Reddy’s Laboratories consolidated net profit plunged 86 per cent at Rs 74.6 crore in the fourth quarter ended March 31, 2016, - See more at: http://ways2capital-equitytips.blogspot.in/2016/05/dr-reddys-q4-net-dives-86-on-venezuelan.html#sthash.5pYCNthR.dpuf
INDIAN EQUITY MARKET OUTLOOK- 23 SEPTEMBER 2016 :Major Headlines of the day: • Wipro to acquire Zhonghsan Ma Er Daily Products • Sun Pharmaceuticals among bidders for Bayer’s dermatology brands • IOC eyes entire GSPC stake in Mundra LNG terminal
Chennai: Drug major Sun Pharmaceutical Industries Ltd on Monday announced the launch of ready-to-administer cancer drug Gemcitabine InfuSMART in Europe. In a statement, the company said InfuSMART is a technology in which oncology/cancer products were developed in a ready-to-administer bag. "Until now, compounding of oncology products was done at compounding centres or compounded in hospi.. Read More
Read more about Sun Pharma secures nod for Ximino capsules on Business Standard. Company expects the extended-release capsules used for treating acne vulgaris will be available for patients during the fourth quarter of 2015
Lupin Ltd is looking for acquisitions in Japan to maintain its lead in a bid to counter the threat from the entry of Sun Pharmaceutical Industries in that market, reports a business daily. The Japanese drug market is No.2 in the world estimated at US$73 billion.